PR Newswire Clinical TrialsOriginal article
TSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1
Phase 1TSC1 AAV Gene TherapyTSC2 programPositive
AI Analysis
Summary
TSC Alliance and Apertura Gene Therapy completed a preclinical pilot study evaluating an AAV gene therapy approach for TSC1, with plans to continue preclinical development using Apertura's TfR1 CapX capsid technology for both TSC1 and TSC2 programs.
Clinical Trial Data
Phase
preclinical
Outcome Details
Preclinical pilot study completed
Importance:4/10
Sentiment:
0.50
gene therapyAAVTSC1TSC2preclinicalTfR1 CapXrare disease
Read the original article
Published by PR Newswire Clinical Trials on July 30, 2026 12:00 PM